Source: Eur Respir J, 53 (4) 1801655; 10.1183/13993003.01655-2018
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vincent Cottin, Arata Azuma, Ganesh Raghu, Wibke Stansen, Susanne Stowasser, Rozsa Schlenker-Herceg, Martin Kolb. Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. Eur Respir J, 53 (4) 1801655; 10.1183/13993003.01655-2018

Member's Comments

No comment yet.

Related content which might interest you: Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century" Year: 2014 Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Heterogeneity of treatment response in bronchiectasis clinical trials Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Effects of Roflumilast on subclinical atherosclerosis in COPD - a randomized controlled trial Source: International Congress 2017 – Extrapulmonary comorbidities in COPD Year: 2017 Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020 Year: 2021 Measuring bronchodilation in COPD clinical trials Source: Eur Respir J 2004; 24: Suppl. 48, 122s Year: 2004 Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial Source: Eur Respir J, 54 (5) 1802134; 10.1183/13993003.02134-2018 Year: 2019 Safety of formoterol in asthma clinical trials Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Premature discontinuation of patients: a potential bias in COPD clinical trials Source: Eur Respir J 2007; 30: 898-906 Year: 2007 Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: A randomised controlled trial Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care Year: 2012 A randomised controlled trial to investigate the optimal dose and effect of salbutamol for the treatment of acute exacerbations of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002